Thermo Fisher Science Institute在Q3 2023中估计收入为5.79 EPS和11.12B美元,尽管内幕出售,投资者仍对收入有浓厚兴趣。 Thermo Fisher Scientific beat earnings estimates in Q3 2023, reporting $5.79 EPS and $11.12B in revenue, with strong investor interest despite insider selling.

Thermo Fisher Science在10月22日报告Q3收入丰厚, Thermo Fisher Scientific reported strong Q3 earnings on October 22, posting $5.79 EPS, beating estimates by $0.29, and generating $11.12 billion in revenue, a 4.9% year-over-year increase. 包括Univest Finance、Strs Ohio和Hudson Value Partners在内的机构投资者增加了对该公司的股份,而内幕人士出售了131 767股,价值7 650万美元。 Institutional investors including Univest Financial, Strs Ohio, and Hudson Value Partners increased their stakes in the company, while insiders sold 131,767 shares worth $76.5 million. 股票交易额为639.03美元,市场上限为240.09亿美元,“机动购买”分析人的共识评级为625.47美元。 The stock trades at $639.03 with a market cap of $240.09 billion and a "Moderate Buy" analyst consensus rating, targeting $625.47. 该公司在全球范围经营生命科学、诊断和生物药剂服务。 The company operates globally in life sciences, diagnostics, and biopharma services.